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Abstract
Sialic acid binding immunoglobulin-like lectin-7 (Siglec-7) is a trans-membrane receptor carrying immunoreceptor tyrosine
based inhibitory motifs (ITIMs) and delivering inhibitory signals upon ligation with sialylated glycans. This inhibitory function
can be also targeted by several pathogens that have evolved to express sialic acids on their surface to escape host immune
responses. Here, we demonstrate that cross-linking of Siglec-7 by a specific monoclonal antibody (mAb) induces a
remarkably high production of IL-6, IL-1a, CCL4/MIP-1b, IL-8 and TNF-a. Among the three immune cell subsets known to
constitutively express Siglec-7, the production of these pro-inflammatory cytokines and chemokines selectively occurs in
monocytes and not in Natural Killer or T lymphocytes. This Siglec-7-mediated activating function is associated with the
phosphorylation of the extracellular signal-regulated kinase (ERK) pathway. The present study also shows that sialic acid-free
Zymosan yeast particles are able to bind Siglec-7 on monocytes and that this interaction mimics the ability of the anti Siglec-
7 mAb to induce the production of pro-inflammatory mediators. Indeed, blocking or silencing Siglec-7 in primary
monocytes greatly reduced the production of inflammatory cytokines and chemokines in response to Zymosan, thus
confirming that Siglec-7 participates in generating a monocyte-mediated inflammatory outcome following pathogen
recognition. The presence of an activating form of Siglec-7 in monocytes provides the host with a new and alternative
mechanism to encounter pathogens not expressing sialylated glycans.
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Introduction
Sialic acid-binding immunoglobulin-like lectins (Siglecs) are a
family of trans-membrane proteins generally transmitting inhib-
itory signals to immune cells upon ligation with their natural
ligands, the sialylated carbohydrates [1,2]. Several pathogenic
microorganisms including Neisseria meningitidis, Group B streptococci,
Trypanozoma cruzi have evolved to synthesize or capture sialic acids
and incorporate these into their own glycoconjugates [3,4,5,6,7].
In this regard, there is a general agreement about the fact that
pathogens learnt to express sialic acids on their surfaces to evade
the hosts’ innate immune responses by targeting the inhibitory
functions of Siglecs. Indeed, syialylation of glycoconjugates in
pathogens appears to be crucial for pathogen survival, possibly
serving as molecular mimics of host immune cell surface to avoid
immune attack. Recently, a novel working hypothesis has emerged
and it suggests that Siglecs have also evolved in response to the
manipulation of immune responses by pathogens to provide the
host with additional new activating pathways to fight pathogenic
microorganisms [2,5,8,9].
Siglec-7 (CDw328), a type 1 trans-membrane protein first cloned
in 1999 and belonging to the human CD33-related Siglec receptors,
is characterized by a sialic acid binding N-terminal V-set Ig domain,
two C2-set Ig domains and an intracytoplasmic region containing
one immune-receptor tyrosine based inhibitory motif (ITIM) and
one ITIM-like motif. Siglec-7, also termed p75/AIRM1, is
constitutively expressed on natural killer (NK) cells, monocytes
and on a small subset of CD8+/CD3+ T cells. The extracellular
domain of this receptor preferentially binds a (2,8)-linked disialic
acids and branched a 2,6-sialyl residues, such as those displayed by
ganglioside GD3 [10,11,12]. Similar to the other members of its
family, the Siglec-7 binding site is generally masked at the cellular
surface due to cis interactions with abundantly expressed low affinity
sialic acids. Unmasking can occur after cellular activation or
sialidase treatment, which cleaves the cis interacting low affinity
ligands and makes it possible for free interactions in trans with highly
glycosylated ligands. Even when Siglecs are masked by cis
interactions, trans interactions might occur during encounters with
other cells or pathogens expressing higher affinity ligands competing
with cis [1,13]. As for interactions with pathogens, Siglec-7 has been
shown to bind Pseudomonas aeruginosa and Campylobacter jejuni,
although neither the signaling pathway(s) involved in these
recognitions nor potential mechanism(s) of endocytosis have been
disclosed [14,15]. We previously reported that the surface
expression of Siglec-7 on NK cells is remarkably decreased in
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HIV-1 infected patients with high levels of ongoing viral replication,
thus suggesting that a direct binding between Siglec-7 and HIV-1
might occur as it has been demonstrated for Siglec-1 [16,17].
The inflammatory response mediated by monocytes following
pathogen recognition is usually triggered by different Pathogen
Recognition Receptors (PRRs), which are naturally able to
recognize highly conserved molecules on microbes. Toll like
receptors (TLRs) represent the best-known PRRs, but others exist.
Indeed, surface receptors like mannose receptor, dectin-1, the
cytosolic receptors nucleotide-binding oligomerization domain-like
receptor family (NLR) and retinoic acid inducible gene I (RIG-I)
belong to the family of PRRs and are involved in pathogen
recognition. In this context, several studies have demonstrated that
pathogens can interact simultaneously with many PRRs and the
subsequent immune responses are likely dependent on all
downstream signals delivered by the engaged receptors
[18,19,20]. Although Siglec-7 is a lectin-type receptor that shares
with several PRRs a similar molecular structure and a clear ability
to bind pathogens, it has been shown to strongly inhibit NK cell
cytotoxicity and to negatively regulate T cell receptor signaling
[10,21]. However, the functional outcome of Siglec-7 in mono-
cytes and following pathogen recognition is still largely unclear
and remains to be determined.
Here, we provide evidence that the engagement of Siglec-7
induces a selective inflammatory response in primary human
monocytes. We show that cross-linking of Siglec-7 by a specific
monoclonal antibody (mAb) on total peripheral blood mononu-
clear cells (PBMCs) triggers a remarkably high production of
several pro-inflammatory cytokines and chemokines exclusively
within the monocyte compartment. Blocking or silencing Siglec-7
in primary monocytes incubated with Zymosan yeast particles
greatly reduces the production of inflammatory mediators, thus
confirming that Siglec-7 participates in generating a monocyte-
mediated inflammatory outcome upon pathogen recognition in
the absence of a sialic-acid microenvironment.
Results
Ligation of Siglec-7 Induces the Production of Pro-
inflammatory Molecules Selectively in Monocytes
To evaluate Siglec-7 functions, we incubated total PBMCs in
96 flat-bottom well plates coated with Z-176, an IgG2b mAb
specifically directed against Siglec-7. After 18 hours of
incubation at 37uC, we collected cell supernatant and
performed a semi-quantitative protein array detecting 507
different soluble proteins. Among the several molecules that
showed to be differently modulated, we observed that the cross-
linking of Siglec-7 in PBMCs triggered the production of IL-6,
IL-1a and induced higher amounts of IL-8 and CCL4/MIP-1b
compared to PBMCs incubated either with the IgG2b matched
(Figure 1) or with the IgG1 unmatched (data not shown) isotype
controls. There are also other molecules, such as Growth
Related Oncogen (GRO) and a deadenylating nuclease (DAN),
whose secretion was induced by the engagement of Siglec-7.
GRO belongs to a family of chemokines specialized for
monocyte arrest from flow [22], while DAN 8 also known as
poly(A)-specific ribonuclease (PARN) or polyadenylate-specific
ribonuclease) is the founding member of the transforming grow
factor beta antagonists [23].
To confirm these data and to also identify the cellular
compartments involved in the production of most relevant
cytokines and chemokines upon Siglec-7 engagement, we
performed a multicolor flow cytometry experimental approach
detecting the intracellular levels of the above-mentioned
inflammatory molecules within immune cells constitutively
expressing Siglec-7: CD3neg/CD19neg/CD56pos NK cells,
CD3pos/CD8pos T cytotoxic cells and CD14pos monocytes
(Figure S1) [1,10,11,16]. We could not detect any NK cell- or
T cell-mediated production of IL-6 upon cross-linking of Siglec-
7, thus indicating that neither CD56bright and CD56dim NK cell
subsets nor CD3pos/CD8pos T cells are accountable for the
Siglec-7-induced synthesis of this cytokine. In contrast, we found
that the engagement of Siglec-7 on CD14pos monocyte triggered
the production of high levels of IL-6, while the intracellular
levels of IL-6 produced by monocytes in the presence of both
IgG2a matched and IgG1unmatched (data not shown) isotype
controls were undetectable (Figures 2 A–B and S1). In line with
the data illustrated in Figure 1, our results also show that the
ligation of Siglec-7 with its specific mAb induced selectively in
monocytes the production of IL-1a and increased significantly
the production of CCL4/MIP-1b and IL-8 over isotype controls
(Figure 2 A–B). Moreover, we measured the intracellular levels
of other important pro-inflammatory cytokines not included in
the 507-protein array: TNF-a, IL1-b and IFN-c. We found that
the cross-linking of Siglec-7, but not the ones given by either
matched (Figure 2 A–B) or unmatched (data not shown) isotype-
controls, triggered the production of TNF-a selectively in
monocytes. We did not detect any intracellular levels of IL1-b
and IFN-c in any of the immune cells constitutively expressing
Siglec-7 (data not shown). Similar to IL-6, we did not observe
any Siglec-7-induced production of IL-1a, MIP-1b, IL-8 and
TNF-a by NK and T cells upon cross-linking of Siglec-7 (data
not shown).
In order to confirm the real specificity of Siglec-7 in
triggering the synthesis of pro-inflammatory cytokines and
chemokines selectively in monocytes, we also cross-linked
Siglec-9, another CD33-related lectin-type receptor that shares
with Siglec-7 a similar structure and cellular distribution [1,2].
We observed that the engagement of Siglec-9 with a specific
anti-siglec-9 mAb, differently from Siglec-7, did not induce any
significant production of IL-1a and TNF-a, measured as
representative pro-inflammatory cytokines (Figure 3A). Finally,
we triggered Siglec-7 function also on freshly isolated monocytes
and also these experiments confirmed that the cross-linking of
this lectin-type receptor on a pure population of monocytes
induce or significantly increase the production of IL-6, IL-1a,
MIP-1b, IL-8 and TNF-a if compared to isotype controls
(Figure S2). The only differences we could observe is that the
amount of the cytokines/chemokines produced upon engage-
ment of Siglec-7 was lower in purified monocytes compared to
those of total PBMCs, thus suggesting that cellular interactions
might be relevant to provide stronger signals.
Since our data demonstrate that the ligation of Siglec-7 can
elicit a monocyte-mediated inflammatory response and consider-
ing also that the migration of monocytes to inflamed tissue is
dependent on adhesion to endothelia and extracellular matrix
proteins [24], we tested whether the stimulation of Siglec-7 was
also associated with an up-regulation of the following adhesion and
co-stimulatory molecules in monocytes: CD11b, CD11c, CD18,
CD49d, CD49e, ICAM-1, CD80 and CD86. Our results showed
that the surface levels of the adhesion molecules ICAM-1 (CD54)
and CD49e were significantly increased on monocytes incubated
with the anti Siglec-7 mAb compared with those of monocytes
incubated with isotype controls (Figure 3 B–C). In contrast, the
expression of the other molecules tested was not affected by the
engagement of Siglec-7 (data not shown).
Siglec-7 Triggers Inflammation in Monocytes
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Phosphorylation of ERK is Associated with the
Engagement of Siglec-7 in Monocytes
The induction of an inflammatory response following the cross-
linking of Siglec-7 is in agreement with another report showing
that the treatment of human monocytes with an anti-CD33 mAb
induced the Siglec-3-mediated production of IL-1, TNF-a and IL-
8 [25]. Furthermore, several studies have recently pointed out that
trans-membrane receptors containing ITIM may sometimes
stimulate rather than repress cellular activation depending on
the cellular context and that this ‘‘activating’’ ITIM cascade can
be mediated by the extracellular signal-regulated kinases (ERK)
pathway [26,27,28,29,30,31,32,33]. Therefore, we tested whether
or not the engagement of Siglec-7 in monocytes is associated with
the phosphorylation of ERK. To this end, we incubated freshly
purified monocytes either with the anti-Siglec-7 mAb or with the
matched IgG2b isotype control in time-course experiments. We
then analyzed the phoshorylation of ERK 1–2 by phospho-flow
cytometry and compared it to phosphorylation given by the anti-
p38 mitogen-activated protein kinases (MAPK), another important
signaling pathway involved in the induction of many genes
encoding inflammatory mediators [34]. Our data showed that the
cross-linking of Siglec-7 was associated with detectable levels of
phosphorylation of ERK 1–2 after 15 minutes of incubation, while
it did not trigger the phosporylation of p38 MAPK. We could not
detect any phosphorylation of ERK 1–2 and p-38 MAPK upon
ligation the IgG2b matched isotype control (Figure 4). We then
further validated the Siglec-7-induced phosporylation of ERK 1–2
by performing western blots. This additional experimental
approach confirmed that the incubation of monocytes with the
anti-Siglec-7 mAb for 15 minutes is indeed associated with an
increased phosphorylation of ERK 1–2 as compared to that given
by the matched isotype control. Indeed, although the detection of
phosphorylated ERK 1–2 was expected even in monocyted
treated with the IgG2b isotype control [35], the relative fold
increase of ERK 1–2 phosphorylation in monocytes incubated
with the anti-Siglec-7 mAb was of 32% higher than the one seen in
monocytes stimulated with the IgG2b isotype control, calculated as
an average of 3 independent experiments.
Siglec-7 Contributes to the Establishment of
Inflammatory Responses Following Recognition of Sialic
Acid-free Pathogens
The fact that the cross-linking of Siglec-7, as well as of Siglec-3
[25], is associated with a monocyte-mediated pro-inflammatory
response insinuates that a sialic-acid-independent alternative
mechanism(s) of pathogen recognition might be possible. To
Figure 1. Detection of cytokines in PBMC supernatant upon engagement of Siglec-7. Secretion of IL-6, IL-1a, IL-8, CCL4/MIP-1b, GRO and
DAN in the supernatant of PBMCs stimulated with the anti-Siglec-7 mAb (right panel) compared with that of PBMCs incubated with a matched IgG2b
isotype control (left panel). The culture medium was collected and analysed using a semi-quantitative protein array detecting simultaneously 507
human soluble proteins. Data shown in this figure are representative of 3 independent experiments.
doi:10.1371/journal.pone.0045821.g001
Siglec-7 Triggers Inflammation in Monocytes
PLOS ONE | www.plosone.org 3 September 2012 | Volume 7 | Issue 9 | e45821
validate this working hypothesis, we incubated different pathogens
that either express or not express sialylated carbohydrates with a
human Siglec-7 Fc chimera and we detected their ability to
interact with the Siglec-7 fusion protein (Figure S3A). As expected,
we observed that Siglec-7 is able to bind Escherichia coli (strain K1)
and Candida albicans, two microbes known to express sialic acids
[36,37]. Surprisingly, we also found that Siglec-7 interacted with
the strain K12 of Escherichia Coli, which has not been reported to
express sialylated carbohydrates (Figure 5). We could not detect
any interactions between the above-mentioned pathogens and
goat anti-human Fc Abs alone, which were used as negative
control.
In order to confirm the real ability of Siglec-7 to bind microbes
not expressing sialic acid residues and to investigate the functional
correlates of these unexpected interactions, we analyzed the ability
of Siglec-7 to bind Zymosan, a cell wall preparation derived from
Saccharomyces cerevisiae that is widely used in vitro for the study of
pathogen-host interactions [38]. Moreover, Zymosan yeast particles
have not been reported to contain sialic acid residues and are well
known for their ability to trigger the production of inflammatory
cytokines and chemokines in immune cells through the binding of
several Zymosan components (b-glucans, mannans, proteins, lipids)
to different PRRs in human PBMCs and macrophages [39,40,41].
In line with what we observed with the acid sialic-free strain K12
of Escherichia coli (Figure 5), the Siglec-7 fusion protein was able to
also bind Zymosan, while we could not detect any interactions of
Zymosan with the goat anti-human Fc mAb alone or with NKp44
Fc chimera, another fusion protein used as a second negative
internal control (Figure 6A–B). We then proceeded to detect the
binding between Siglec-7 and Zymosan on freshly purified
monocytes that constitutively express this receptor on their cell
surface [1]. To this end, we incubated adherent monocytes with
Zymosan and evaluated the localization of both Siglec-7 and the
yeast particles on cell surface by confocal microscopy (Figure S3B).
After 30 minutes of incubation there was a striking polarization of
Siglec-7 distribution toward the pathogen and we also observed a
co-localization of Siglec-7 and Zymosan on monocyte cell surface
(Figure 6C).
We then proceeded to assess if Siglec-7 played any role in
inducing a monocyte-mediated production of pro-inflammatory
cytokines and chemokines following Zymosan recognition. To this
end, we incubated freshly purified monocytes with these yeast
particles in the presence or in the absence of polyclonal Abs
neutralizing Siglec-7. Similar to previous reports [39,40,41], we
observed that exposure of monocytes to Zymosan induced a
remarkable production of both TNF-a and IL-1a. The masking of
Siglec-7 with an anti-Siglec-7 Abs resulted in a statistically
significant reduced production of TNF-a and IL-1a in monocytes
(Figure 7). To further confirm the specific role of Siglec-7 in
triggering an inflammatory response in primary monocytes upon
Figure 2. Intracellular production of pro-inflammatory cytokines and chemokines in monocytes upon engagement of Siglec-7. (A)
Representative flow cytometry dot plot graphs showing the percentage of CD14pos monocytes, within total PBMCs, producing IL-6, IL-1a, CCL4/MIP-
1b, IL-8 and TNF-a after incubation with either the anti-Siglec-7 mAb (lower line) or the matched IgG2b isotype control (upper line). (B) Statistical
summary graphs of dot plots with medians (horizontal black bars) and p values showing the percentage of CD14pos monocytes producing IL-6, IL-1a,
MIP-1b, IL-8 and TNF-a in response to either the anti-Siglec-7 mAb (red circles) or the matched IgG2b isotype control (green circles).
doi:10.1371/journal.pone.0045821.g002
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binding with Zymosan, we performed mRNA silencing experi-
ments. As shown in Figure 8A, we were able to markedly reduce
the surface levels of Siglec-7 (up to 75%) in monocytes transfected
with SiRNA duplexes specific for Siglec-7. We then exposed these
monocytes silenced for Siglec-7 to Zymosan. This additional set of
experiments confirmed that the levels of production of TNF-a and
IL-1a were significantly lower in monocytes silenced for Siglec-7
compared to those of monocytes transfected with control non-
targeting probes (scrambled SiRNA) (Fig. 6B). The same reduction
was also obtained in regard to the production of IL-6, MIP-1b and
IL-8 (data not shown). Taken together, these experimental results
indicate that Siglec-7 actively participates in the enhancement of
inflammatory responses by monocytes after pathogen recognition.
Discussion
In the present study, we demonstrate that the engagement of
Siglec-7 induces the production of TNF-a, IL-1a, IL-6, IL-8 and
MIP-1b. The induction of this inflammatory response following
ligation of Siglec-7 with a specific anti-Siglec-7 mAb is restricted to
monocytes and does not occur in NK and T lymphocytes, the
other two cell subsets constitutively expressing Siglec-7. This novel
activating function of Siglec-7 is also corroborated by the fact that
its cross-linking in monocytes leads to the phoshporylation of ERK
1–2, an important and well-established signaling pathway that
activates a variety of transcription factors coordinating the
modulation of many genes involved in the establishment of
inflammatory responses [42]. We also show here that, other than
binding pathogens expressing syalilated glycans, Siglec-7 can also
interact with microbes not reported to be conjugated with sialic
acid residues such as the strain K12 of Escherichia coli and Zymosan
yeast particles. These findings provide novel mechanistic insights
on the monocyte responses following the recognition of pathogens
not expressing sialylated carbohydrates. Indeed, we also demon-
strate here that masking or silencing Siglec-7 in monocytes
incubated with Zymosan substantially reduced the production of the
above-mentioned cytokines and chemokines, thus confirming that
this CD33-related lectin-type receptor significantly contributes to
prime an inflammatory outcome in monocytes.
The undetectable intracellular levels of the above-mentioned
cytokines and chemokines after incubation with both IgG2a
matched and IgG1 unmatched isotype negative controls indicate
that the production of these pro-inflammatory molecules by
monocytes is not associated with a non-specific binding between
the Fc portion of mAbs and the CD16/FccIII receptor, but is
rather triggered by a selective cross-linking of Siglec-7. In this
regard, PBMCs were also pre-incubated with human IgG
antibodies that masked the CD16/FccIII receptor expressed on
monocytes and NK cells, thus avoiding non-specific interactions
with the FC portion of mAbs. Indeed, the fact that we could not
detect any NK cell-mediated synthesis of IL-6, IL-1a, MIP-1b, IL-
8 and TNF-a either using anti-Siglec-7 mAb or isotype controls
confirms one more that this phenomenon s associated with a
selective engagement of Siglec-7 on monocytes and not to a non-
specific stimulation of the CD16/FccIII receptor.
The previously reported inhibitory function of Siglec-7 in
regulating T cell receptor signaling and NK cell cytolytic activity
reflects the structure of this ITIM-bearing receptor [1,10,21]. In
this regard, it is widely accepted that the immune system employs
negative regulation mechanisms of cellular responses through a
large family of receptors containing ITIMs. Ligand engagement by
these inhibitory receptors results in ITIM phosphorylation by Src
Figure 3. Intracellular production of TNF-a and IL-1a in monocytes upon engagement of Siglec-7 and Siglec-9 and modulation of
adhesion molecules in monocytes upon engagement of Siglec-7. (A) Statistical histogram bar graph showing the percentages of CD14pos
monocyte producing TNF-a (left) and IL-1a (right) in the presence of mAbs cross-linking either Siglec-7 and Siglec-9 or their relative IgG2b and IgG1
isotype controls. Data are representative of 5 independent experiments performed in triplicates (6 SD). (B) Representative flow cytometry histogram
graphs showing the mean fluorescence intensity (MFI) of ICAM-1 (left) and CD49e (right) on CD14pos monocyte after incubation with either the anti-
Siglec-7 mAb (blue lines) or with the matched IgG2b isotype control (red lines). (C) Statistical summary graphs of box plots with medians and
standard deviation showing the MFI of ICAM-1 (left) and CD49e (right) on CD14pos monocyte after incubation with either the anti-Siglec-7 mAb (blue
boxes) or with the matched IgG2b isotype control (red boxes). Data are representative of 5 independent experiments (6 SD).
doi:10.1371/journal.pone.0045821.g003
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family kinases, which, in turn, recruit phosphotyrosine phospha-
tase (PTP) such as Src homology region 2 domain-containing
phosphatase-1 (SHP-1) and SHP-2. PTP recruitment switches off
cellular pathways by decreasing tyrosine phosphorylation. More-
over, the engagement of inhibitory receptors containing ITIMs
also prevents the activation signals that originate from receptors
associated with immunoreceptor tyrosine based activating motifs
(ITAMs) [43]. However, within the past few years, the interpre-
tation of this antipathetic receptor-signaling paradigm has become
less rigorous as the number of newly identified trans-membrane
receptors containing ITIMs increases. Indeed, several studies
recently reported that, in some circumstances and depending on
the cellular context, ITIMs can propagate activation signals and
ITAMs can mediate inhibition [26,27,28,29,30,31,32,33]. This is
the case of dendritic-cell-associated C-type lectin 2 (DCAL-2), an
ITIM bearing receptor, whose ligation with an anti-DCAL-2 mAb
recruits a SHP-2 domain that, instead of negatively regulating cell
signaling, is involved in activating the ERK pathway and in
inducing the production of IL-10, TNF-a, IL-6 and MIP-3b [26].
Many other ITIM-bearing receptors have been shown to recruit
these ‘‘atypical’’ PTPs (both SHP-1 and -2) that partially explain
the ambiguity of ITIM in immune-receptor signaling [28]. In line
with these experimental evidences, we demonstrate here that the
cross-linking of Siglec-7 by an anti-Siglec-7 mAb is also associated
with the phosphorylation of the ERK pathway in monocytes.
Hence, our results strongly suggest that the Siglec-7 isoform(s)
Figure 4. Phosphorylation of ERK upon engagement of Siglec-7 in monocytes. (A) Representative phospho-flow cytometry dot plot graphs
showing the percentage of phosphorylation of p38 MAPK and of ERK 1–2 in freshly purified monocytes incubated with an IgG2b isotype (left column)
and anti Siglec-7 mAb (right column) at time 0 (upper line) and after 5 (middle line) and 15 (lower line) minutes of incubation. The number
highlighted in bold red within the lower right quadrant of the dot plot graph located in the lower line of right column indicates the phosphorylation
of ERK following ligation of Siglec-7. (B) Representative western blot image showing the phoshorylation of ERK 1–2 in freshly purified monocytes
stimulated with IgG2b isotype (left) and anti Siglec-7 mAb (right) after 15 minutes of incubation. Data are representative of 3 independent
experiments (6 SD).
doi:10.1371/journal.pone.0045821.g004
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expressed selectively on monocytes and not on T and NK cells
belongs to the family of ‘‘activating’’ ITIM bearing receptors.
Moreover, it has been shown that Siglec-7 inefficiently recruits
PTP and that this phenomenon greatly affects the downstream
signaling of this lectin-type receptor. In fact, introduction of a
triple mutation into the Siglec-7 sequence greatly enhanced PTP
recruitment and increased the inhibitory activity of the mutant
close to that of Siglec-9 [44]. These experimental evidence
indicate that the inhibitory potential of Siglec-7 is generally weaker
compared to the one of other Siglecs or ITIM bearing receptors
following cellular activation. Whether this weak recruitment of
PTPs affects the inhibitory function of selected isoform(s) of Siglec-
7 expressed on a particular cell subset or if this generally occurs in
all immune cells constitutively expressing Siglec-7 is still not
known. In any case, the weak engagement of PTP might be one of
the reasons explaining the fact that Siglec-7, in contrast to other
CD33-related receptors, does not induce apoptosis of leukemic
cells while keeps the potential to inhibit their proliferation [45].
Both the weak recruitment of regular PTPs and/or the engage-
ment of atypical activating forms of these phosphatases upon
ligation of Siglec-7 in monocytes might explain the presence of a
partial phosphorylation of the ERK pathway, as observed in our
experiments. Therefore, our functional characterization of an
activating form of a Siglec-7 containing ITIM domains follows the
most recent updates in this research field, although deciphering
the complex scenario of the immune-biology of ITIM and ITAM
bearing receptors certainly represents an important challenge for
better understanding the physiology and physiopathology of
immune-receptor signaling.
The present study also reports that cross-linking of Siglec-7 on
monocytes induced an up-modulation of two important adhesion
molecules: ICAM-1 and CD49e. Interestingly, interactions
between ICAM-1 with either b2 integrins lymphocyte function-
associated antigen (LFA-1) or Macrophage 1 antigen (Mac-1) on
endothelial cells induce transmigration of leukocytes during
inflammatory responses. Moreover, ICAM-1 interaction with
LFA-1 can deliver a co-stimulatory signal to T cells [46]. CD49e
is an adhesion molecule that associates with CD29 to form integrin
VLA-5, a fibronectin receptor [47]. Hence, the ligation of Siglec-7,
other than inducing a monocyte-mediated inflammatory response,
might also be important in regulating the migration of leukocytes
toward sites of inflammation and in delivering co-stimulatory
signals. The activation and the migration of monocytes to tissues
lead to a plastic polarization toward M1 or M2 macrophages that
depends from a variety of signals within the local micro-
environment [48]. Although Siglec-7 is also expressed on
macrophages (data not shown), it remains to be determined
whether the engagement of this lectin-type receptors still trigger
activating signals in macrophages or interfere with macrophage
plasticity to undergo classic or alternative polarization.
Figure 5. Binding of pathogens to Siglec-7 Fc chimera. Representative flow cytometric dot plot graphs showing the binding of goat anti
human (GAH) Fc Ab (upper line) and of Siglec-7 Fc chimera (lower line) to Escherichia coli (strains K1 and K12) and Candida albicans. Data are
representative of 3 independent experiments.
doi:10.1371/journal.pone.0045821.g005
Siglec-7 Triggers Inflammation in Monocytes
PLOS ONE | www.plosone.org 7 September 2012 | Volume 7 | Issue 9 | e45821
Interest in Siglecs has grown remarkably in the recent few years
as it has become evident that these receptors, broadly expressed on
cells within the innate immune compartment and mostly
mediating inhibitory signals upon ligation with sialylated carbo-
hydrates, play a wide range of roles. Originally, the first reported
function of Siglecs was to dampen host immune responses and set
appropriate activation thresholds for regulating cellular growth,
survival and the production of soluble mediators [1,2]. Subse-
quently, it also became clear that, during the course of evolution,
several pathogenic microorganisms have learned to synthesize or
capture sialic acids in order to bind Siglecs and escape immune
responses. Based on this, a novel and emerging working hypothesis
postulates that CD33-related Siglecs also evolved in response to
pathogen manipulation by associating their intracellular domains
with either activating ITIMs, as previously described, or even with
ITAM domains containing the adaptor molecule DAP12, as it has
been described for Siglec-16 [8]. Our results are in line with this
last experimental evidence by demonstrating that also Siglec-7
evolved to counterpart the gained ability of pathogens to
synthesize or capture sialic acids in order to bind Siglec receptors
and escape immune responses. To this end, Siglec-7 learnt to
trigger activating signals in monocytes and to bind also sialic-free
pathogens with the aim of providing optimal immune and
inflammatory responses against pathogens. Blocking this function
would theoretically give back to pathogens the possibility to evade
innate immune responses. In this regards, Siglec-7 has already
been reported to bind sialylated glycans either expressed by
Campylobacter jejuni or acquired by Pseudomonas aeruginosa [14,49].
Figure 6. Binding of Zymosan to Siglec-7 Fc chimera and to Siglec-7 receptor expressed on freshly putified monocytes. (A)
Representative flow cytometric dot plot graphs showing the binding of goat anti human (GAH) Fc Ab (left), NKp44 Fc chimera (middle) and Siglec-7
Fc chimera (right) to Zymosan. (B) Fluorescent microscopic images of Zymosan particles (gray, left part of the panel) surrounded by PE-labeled Siglec-
7 Fc chimera (green, right part of the panel). (C) Fluorescent microscopic images of primary monocytes labeled for Siglec-7 (red) and incubated with
Zymosan particles (green) for 5 and 30 minutes. The co-localization is labeled in yellow.
doi:10.1371/journal.pone.0045821.g006
Figure 7. Zymosan-induced production of TNFa and IL-1a:mask-
ing of Siglec-7. Statistical histogram bar graph showing the
percentages of CD14pos monocyte producing TNF-a (left) and IL-1a
(right) either in the absence (gray bars) or in the presence (white bars)
of Zymosan and in presence of Zymosan cultured with blocking anti-
Siglec-7 Abs (black bars). The intracellular production of TNF-a and IL-1a
were evaluated by flow cytometric analysis. Data are representative of 5
independent experiments performed in triplicates (6 SD).
doi:10.1371/journal.pone.0045821.g007
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Here, we confirm that Siglec-7 is indeed able to bind other
pathogens expressing sialylated glycans such as strain K1 of
Escherichia coli and Candida albicans [36,37], but we also demonstrate
the capacity of this CD33-related lectin-type receptor to interact
with microbes not reported to express sialic acids such as the strain
K12 of Escherichia coli and Zymosan yeast particles. In particular, our
data showed that both Siglec-7 fusion protein and Siglec-7
receptor expressed on freshly purified monocytes bind Zymosan.
Moreover, confocal images revealed that incubation of adherent
monocytes with Zymosan induced a clear polarization of Siglec-7
towards the pathogen that co-localized with this lectin-type
receptor at the binding site, thus supporting the role of Siglec-7
in pathogen recognition.
Our flow cytometry experiments also displayed that that the
intensity of the binding (evaluated by mean fluorescence intensi-
ties) of Siglec-7 and the strain K12 of Escherichia coli is different
compared to that of Zymosan, thus suggesting a different interaction
affinity. Further studies are needed to disclose the nature and the
kinetics of these sialic-acid independent bindings in order to
disclose the Siglec-7 epitope(s) able to binds several and different
pathogens. The scope of the present study is to assess whether, in
the absence of the already reported sialic acid-mediated repressor
activity of CD33 and CD33-related siglec molecules on immune
cells [1,2,8,25], Siglec-7 participates in the development of
inflammation following pathogen recognition. This working
hypothesis relies on the two above-reported experimental
evidence: i) the ability of Siglec-7, as well as of CD33 [25], to
trigger the production of pro-inflammatory cytochines and
chemokines when cross-linked with a specific anti-siglec-7 mAb
and ii) its capacity to bind sialic-acid-free pathogens. In fact, our
data demonstrates that the incubation of monocytes with Zymosan,
a sialic acid-free microbe widely used in vitro host-pathogen
interactions [38], is indeed associated with a massive production of
TNF-a and IL-1a. However, it is well known that the recognition
of Zymosan by monocytes/macrophages occurs primarily through
the engagement of different PRRs, including Dectin 1 and TLR2,
Figure 8. Zymosan-induced production of TNFa and IL-1a: silencing of Siglec-7. (A) Representative graphs showing the intracellular
production of TNF-a and IL-1a in monocytes transfected either with non-targeting SiRNA control probes (green line in the histogram graph and dot
plot graphs in the upper line of the panel) or with SiRNA duplexes specific for Siglec-7 (red line in the histogram graph and dot plot graphs in the
lower line of the panel) in response to Zymosan. MFI: Mean Fluoresence Intensity. Filled gray Histogram: isotype control. (B) Summary graphs of dot
plots (left) and statistical summary bar graphs with p values and standard deviation (right) showing the percentages of decrement of TNF-a (left) and
IL-1a (right) in monocytes silenced for Siglec-7 compared to monocytes not silenced for Siglec-7 in response to Zymosan. Data are representative of 5
independent experiments (6 SD).
doi:10.1371/journal.pone.0045821.g008
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two proteins that synergize in the induction of inflammatory
responses [40]. Nevertheless, masking or silencing Siglec-7 in
primary monocytes incubated with Zymosan greatly reduced the
production of pro-inflammatory cytokines, thus demonstrating a
clear contribution of Siglec-7 in triggering inflammation following
the recognition of pathogens not expressing syalilated glycans. The
fact that the production of pro-inflammatory mediators was not
completely abrogated after blocking or silencing Siglec-7 confirms
once again that different PRRs are required to trigger an
inflammatory response in monocytes and that Siglec-7 is one of
the actors playing an active role in this scenario. The synergy of
Siglec-7 with other PRRs in triggering the activation of monocytes
in response to pathogens remains to be determined. In this
context, an important factor to consider is that the threshold for
glycan recognition is a function of the density of membrane-bound
and this greatly affects pathogen recognition and, as a conse-
quence, the antagonistic or synergic activation of signaling
pathways [50]. Hence, additional studies are required to address
the kinetic and the interaction of Siglec-7 with other PRRs in
monocytes, that differently from the other two lymphocyte subsets
constitutively expressing Siglec-7 (i.e. NK and T cells), are innate
effectors designated to bind and phagocitate microbes, and to
subsequently induce inflammatory responses.
In conclusion, the present study demonstrates a novel activating
role of Siglec-7 in monocytes but not in T and NK cells, the other
two immune cell subsets constitutively expressing this CD33-
related lectin-type receptor. Indeed, although the glycobiology of
Siglec-7 (as well as of Siglecs in general) has been extensively
investigated over the past decade, only a few studies disclosed the
functional immune correlates of this receptor and none of these
reports have analyzed Siglec-7 functions within the monocyte
compartment. We show here that Siglec-7 ligation with an anti-
Siglec-7 mAb is able to induce an inflammatory outcome
selectively in monocytes. The activating role of Siglec-7 also
occurs when sialic acid-free Zymosan yeast particles binds this
lectin-type molecule on monocytes. This indicates that the
engagement of Siglec-7 contributes in developing inflammation
in response to pathogenic microorganisms not expressing syali-
lated glycans at least in certain cellular contexts. Our findings open
new perspectives in the field by disclosing a new function of the
Siglec-7 innate immune receptor following pathogen recognition.
Materials and Methods
Isolation of PBMCs and Monocytes
Human PBMCs were obtained from buffy coats and healthy
volunteers signed consent forms in accordance with clinical
protocols approved by the Institutional Review Board of Desio
Hospital, Milan, Italy. The percentage of monocytes within the
white cell compartment of all healthy donors tested is comprised
within the normal range of 10% and no one of the donors showed
high titers of serum antibodies in any of their sub-classes (IgM,
IgG, sIgA). PBMCs were isolated over Ficoll-Hypaque gradient
centrifugation (Amersham Pharmacia Biotech) and CD14pos and/
or CD16pos monocytes were purified from PBMCs by negative
magnetic cell sorting technique (EasySep Human Monocyte
Enrichment Kit, Stemcell Technologies) according to the protocol
provided by the manifacturer. This experimental approach
allowed us to isolate all CD3neg, CD19neg, CD56neg monocytes
subsets either single o double positive for CD14 and CD16 [51].
Protein Array
96 flat-bottom well plates were coated with 10 mg/ml of anti-
Siglec-7 mAb (clone Z176, IgG2b) (either purchased from
Beckman Coulter or provided by Dr. Alessandro Moretta) or
with the same amounts of either a matched IgG2b or an
unmatched IgG1 isotype controls (Beckman Coulter). After 16
hours of incubation, coated plates were washed twice with PBS
medium (Gibco) supplemented with 2% FCS (Hyclone). 26106/
ml of PBMCs were suspended in 1641 RPMI medium supple-
mented with 10% FCS with penicillin/streptomycin and L-
glutamine (Gibco) and cultured for 18 hours at 37uC in the
previously described coated plates at the final volume of 200 ml/
well. Before culturing the cells in the plates coated with anti-Siglec-
7 mAb, PBMCs were pre-incubated with human IgGs antibodies
(Sigma-Aldrich) at 4uC for 20 minutes to block CD16/FccIII
receptor and to avoid its non-specific bindings with the FC portion
of mAbs. Cell supernatants were then collected and analyzed using
the RayBio Biotin Label-based Human Antibody Array that
allows the detection of 507 different proteins, following manufac-
turer’s instructions (RayBioH Biotin Label-based Human Antibody
Array I, RayBiotech, Inc.).
Flow Cytometry and Confocal Microscopy
2610?/ml of PBMCs or freshly purified monocytes were
incubated as described above in 96 flat-bottom plates coated with
anti-Siglec-7 and anti-Siglec-9 (Biolegend, IgG1) mAbs or with
isotype controls in the presence of monesin (Golgi-Stop, 0,3 ml/ml)
(BD Pharmigen). For multicolour flow cytometric analyses (FACS
Canto II, BD Biosciences), cells were stained with phycoerythrin-
Cy5 labelled CD56 (Beckman & Coulter), phycoerythrin-Cy7
labelled CD3, allophycocyanin-Cy7 labelled CD19, fluorescein
isothiocyanate labelled CD14 (BD Biosciences).
The surface levels of adhesion and co-stimulatory molecules
were detected by using phycoerythrin-labelled anti-CD11b, anti-
CD11c, anti-CD18, anti-CD49d, anti-CD49e, anti- ICAM-1,
CD80 and anti- CD86 mAbs (BD Pharmigen).
For intracellular staining, after an incubation of 30 minutes at
4uC with the above mentioned anti-CD56, -CD3, -CD-19 and -
CD14 labelled mAbs, PBMCs were washed, fixed and permeabi-
lized with cytofix/cytoperm following manufacturer’s instructions
(BD biosciences) and incubated separately for 30 minutes at 4uC
with the following Phycoerythrin labelled anti-cytokine/chemokine
mAbs: anti-IL-6, anti-IL-1a, anti-IL-1b, anti-MIP-1b, anti-IL-8,
anti-TNF-a and anti IFN-c (BD biosciences). Data were analyzed
using FlowJo software (TreeStar).
For binding experiments, Zymosan (Zymosan A, Bioparticles,
Invitrogen), Escherichia coli K-1 (ATCC) and K12 strains (Molec-
ular probes) and Candida albicans (Greer Laboratories) were
incubated for 30 minutes at 37uC with human Siglec-7 and
NKp44-Fc chimeras (R&D Systems) in PBS medium. Pathogens
were then washed twice in PBS and anti-human FC antibodies
labelled with Phycoerythrin (for flow cytometry) or with Alexa 488
(for confocal microscopy) (Invitrogen) were added to the culture
(Figure 4A). After incubating for 30 minutes at 4uC, samples were
washed and analyzed. For confocal microscopy, the samples were
first fixed with paraformaldehyde (PFA) at 4% and the binding
between fusion proteins and Zymosan was then detected with an
Olympus Fluoview FV1000 laser-scanning confocal microscope.
Images (102461024 pixels) were acquired with a 6061.4 NA Plan-
Apochromat oil immersion objective (Olympus, Hamburg,
Germany). Images were processed using Leica TCS-NT/SP
software (version 1.6.587), Imaris 3.3.2 (Bitplane AG), and Adobe
and Photoshop 7.0 (Adobe systems).
For detecting the binding between Siglec-7 receptor and
Zymosan particles on freshly purified monocyte, 250,000 adherent
monocytes were incubated in PBS medium with 16104 particle of
Zymosan directly conjugated with Alexa 488 (Invitrogen). Cells
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were then washed and stained with anti-Siglec 7 mAb (Z176)
followed by Alexa 633 conjugated isotype-specific rat anti-mouse
second Ab (Invitrogen). After washing and fixing with PFA at 4%
cells were cyto-spinned and mounted on glass slides with a
prolonged antifade reagent (ProLongH Gold Antifade Reagent,
Invitrogen). Images were acquired and processed immediately,
after 5, 30 and 60 minutes of incubaton with Zymosan
(Supplemental Fig. 1).
Phospho-flow Cytometry and Western Blot Analysis
For phospho-flow cytometric analyses, 26105/well of freshly
purified monocytes were cultured in complete medium and
incubated in time course experiments (0, 5 and 15 minutes) at
37uC in 96 flat bottom plates coated either with an anti-Siglec-7
mAbs or with a matched IgG2b isotype control. Cells were then
fixed with BD Cytofix Buffer, incubated for 10 minutes at 37uC,
washed twice with PBS-2% FCS and permeabilized with BD
Phosflow Perm Buffer III for 30 minutes on ice. After washing,
cells were incubated for 309 at RT with anti-pERK 1–2 Alexa 488
and anti-p38 PE antibodies.
For Western Blot Analysis, 26105/well of freshly purified
monocytes were incubated at 37uC in time course experiments (0,
5 and 15minutes) with anti-Siglec-7 mAbs or with a matched IgG2b
isotype control in serum free-medium. Cells were then lysed in a
radio-immune-precipitation (RIPA) buffer (50 mM TrisHCl, pH 8,
1% TritonX100, 100 mMNaCl, 1 mMMgCl2) supplemented with
Complete Mini Protease Inhibitor Cocktail (Roche Diagnostics,
Indianapolis, IN) and with 200 mM Sodium fluoride, 10 mM
Sodium pyrophosphate, 100 mM Sodium orthovanadate. Follow-
ing incubation on ice for 30 minutes, cell lysate was centrifuged at
16000 g for 30 minutes at 4uC, boiled for 5 minutes in Leammli
buffer, inserted in a 10% SDS-polyacrylamide gel electrophoresis
(SDS-PAGE) and transferred to nitrocellulose membranes. Immu-
noblotting was performed using primary rabbit polyclonal antibody
specific for phospho-ERK (p44/42; Thr202/Tyr204), detected with
an antirabbit HRP-conjugated Ab and visualized using chemilu-
minescent substrate (Millipore, Bedford, MA, USA). Membranes
were then stripped with hot Stripping buffer (62,5 mM Tris-HCl,
pH 6,8, 100 mM b-mercaptoethanol, 2% Sodium Dodecyl Sul-
phate) and re-probed with rabbit polyclonal antibodies that detected
total ERK 1–2. All antibodies were purchased from Cell Signaling
Technology (Beverly, MA). Radiographic images were quantified
by scanning densitometry and expressed as percent of relative fold
increase. All reagents used for phospho-flow and western blot
experiments were endotoxin-free.
Masking Experiments
Freshly purified monocytes were incubated for 30 minutes at
37uC with 100 mg/ml of Zymosan either in the presence or the
absence of a pre-incubation (1 hour at 4uC) with 10 mg/ml of a
blocking anti-Siglec-7 polyclonal antibody (R&D system). Cells
were washed twice, and the intracellular production of TNF-a and
IL1-a was detected as previously described.
RNA Interference Assay
Siglec-7 silencing on freshly purified monocytes was performed
using Stealth Select RNAiTM siRNA technology following manufacturer’s
instructions (Invitrogen). Briefly, two different pre-designed Siglec-7
siRNA probes provided by Invitrogen (59-GAACUUGACUGU-
GACGUCUUCCAA-39 and 59-GAACAGUGUGUGUCAUU-
CUCUCCAA-39) were annealed with complementary sequences
and successively transfected into monocytes using Lipofectamin 2000
(Invitrogen). A different predesigned SiRNA probe, provided by
Invitrogen, was used as internal control (59-GAGAUACGGGUA-
GAAUAGCGACAAA-39). Cells were incubated at 37uC in com-
plete RPMI medium supplemented with GM-CSF at 10 ng/ul
(Schering-Plough). Surface expression of Siglec-7 on monocyte was
detected after 3 days of incubation by flow cytometry using the anti
Siglec-7 mAb (Z-176) followed by fluorescein isothiocyanate conju-
gated isotype-specific goat anti-mouse second reagent (Southern
Biotechnology Associates). The intracellular production of TNF-a
and IL1-a following Zymosan incubation was detected as previously
described.
Statistical Analyses
Immune response distributions within monocyte populations
were evaluated using non parametric Wilcoxon signed rank tests.
All p values are 2-sided and unadjusted.
Supporting Information
Figure S1 Gating strategy gating within total freshly
purified PBMCs and intracellular production of IL-6
upon engagement of Siglec-7. (A) Within the lymphocyte
gate, T cells were identified on the basis of their CD3 expression,
while the CD3neg/CD19neg/CD56pos phenotype characterized
NK cells. The positivity for CD14 distinguished primary
monocytes within their distinctive gate. (B) Representative flow
cytometry dot plot graphs showing the percentage of CD3pos T
cells (first column), CD56pos NK cells and CD14pos monocytes
producing IL-6 in response to either the anti-Siglec-7 mAb (lower
line) or to the matched IgG2b isotype control (upper line). (C)
Summary graph of dot plots with medians (horizontal black bars)
showing the percentage of freshly purified NK cells, monocytes
and CD8pos T cells constitutively expressing Siglec-7 receptor on
their surface.
(TIF)
Figure S2 Intracellular production of pro-inflammatory
cytokines and chemokines in purified monocytes upon
engagement of Siglec-7. Statistical summary graphs of dot
plots with medians (horizontal black bars) and p values showing
the percentage of freshly purified CD14pos monocytes producing
IL-6, IL-1a, MIP-1b, IL-8 and TNF-a in response to either the
anti-Siglec-7 mAb (red circles) or the matched IgG2b isotype
control (green circles).
(TIF)
Figure S3 Methodology detecting the binding between
Siglec-7 and pathogens. (A) Siglec-7 fusion protein was
incubated with pathogens (Escherichia coli, Candida albicans) or
Zymosan yeast particles and the related binding was detected
trough a goat anti human (GAH) Fc Ab labeled with Phycoer-
ythrin (flow cytometry) or with Alexa Fluor 488 (confocal
microscopy only for experiments with Zymosan). (B) Adherent
monocytes stained with anti human Siglec-7 mAb directly
conjugated with Alexa Fluor 633 were incubated with Zymosan
particles directly conjugated with Alexa Fluor 488.
(TIF)
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